Literature DB >> 22696166

Viewpoints in clinical proteomics: when will proteomics deliver clinically useful information?

Carl A K Borrebaeck1.   

Abstract

Despite massive efforts, proteomics has not delivered biomarkers of clinical value. However, the technologies that are emerging today have the power to reach deep into proteomes and identify the patterns associated with different diseases. Study design is then crucial and sample quality, bioinformatics approaches, prevalidation, using independent patient cohort need to attract increased attention before proteomics will contribute to the needs of personalized medicine.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696166     DOI: 10.1002/prca.201200020

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  3 in total

Review 1.  Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.

Authors:  Carl A K Borrebaeck
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

Review 2.  Integrated Chemometrics and Statistics to Drive Successful Proteomics Biomarker Discovery.

Authors:  Anouk Suppers; Alain J van Gool; Hans J C T Wessels
Journal:  Proteomes       Date:  2018-04-26

Review 3.  Advances in the proteomic discovery of novel therapeutic targets in cancer.

Authors:  Shanchun Guo; Jin Zou; Guangdi Wang
Journal:  Drug Des Devel Ther       Date:  2013-10-24       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.